$MBIO
MUSTANG BIO, INC.

2022 Q4 Form 10-K Financial Statement

#000155837023004979 Filed on March 30, 2023

View on sec.gov

Income Statement

Concept 2022 Q4 2022 2021
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.395M $12.21M $11.02M
YoY Change -9.49% 10.83% 15.85%
% of Gross Profit
Research & Development $16.34M $62.48M $49.86M
YoY Change -2.6% 25.29% 33.91%
% of Gross Profit
Depreciation & Amortization $728.0K $2.700M $2.200M
YoY Change 11.15% 22.73% 29.41%
% of Gross Profit
Operating Expenses $19.43M $76.16M $66.72M
YoY Change -3.41% 14.14% 17.46%
Operating Profit -$76.16M -$66.72M
YoY Change 14.14% 17.46%
Interest Expense -$837.0K -$2.670M $353.0K
YoY Change -1295.71% -856.37% -111.0%
% of Operating Profit
Other Income/Expense, Net $635.0K -$1.366M $353.0K
YoY Change -486.97% -111.0%
Pretax Income -$19.63M -$77.53M -$66.37M
YoY Change -2.07% 16.81% 10.58%
Income Tax
% Of Pretax Income
Net Earnings -$19.63M -$77.53M -$66.37M
YoY Change -2.07% 16.81% 10.59%
Net Earnings / Revenue
Basic Earnings Per Share -$0.75 -$0.76
Diluted Earnings Per Share -$0.18 -$0.75 -$755.2K
COMMON SHARES
Basic Shares Outstanding 103.4M 87.89M
Diluted Shares Outstanding 103.4M 87.89M

Balance Sheet

Concept 2022 Q4 2022 2021
SHORT-TERM ASSETS
Cash & Short-Term Investments $75.66M $75.66M $109.6M
YoY Change -30.98% -30.98% 12.08%
Cash & Equivalents $75.66M $75.66M $109.6M
Short-Term Investments
Other Short-Term Assets $3.160M $3.160M $2.038M
YoY Change 55.05% 55.05% 19.88%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $78.85M $78.85M $111.7M
YoY Change -29.41% -29.41% 12.27%
LONG-TERM ASSETS
Property, Plant & Equipment $9.391M $12.31M $12.10M
YoY Change -15.03% 1.71% 32.99%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $261.0K $1.261M $1.362M
YoY Change -27.9% -7.42% 4.77%
Total Long-Term Assets $13.57M $13.57M $13.46M
YoY Change 0.79% 0.79% 29.46%
TOTAL ASSETS
Total Short-Term Assets $78.85M $78.85M $111.7M
Total Long-Term Assets $13.57M $13.57M $13.46M
Total Assets $92.42M $92.42M $125.2M
YoY Change -26.16% -26.16% 13.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.833M $6.833M $3.512M
YoY Change 94.56% 94.56% 0.34%
Accrued Expenses $7.628M $7.628M $6.749M
YoY Change 13.02% 13.02% 32.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.11M $15.11M $10.82M
YoY Change 39.7% 39.7% 13.84%
LONG-TERM LIABILITIES
Long-Term Debt $27.44M $27.44M $0.00
YoY Change
Other Long-Term Liabilities $3.604M $3.604M $1.955M
YoY Change 84.35% 84.35% -2.25%
Total Long-Term Liabilities $31.04M $31.04M $1.955M
YoY Change 1487.72% 1487.72% -2.25%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.11M $15.11M $10.82M
Total Long-Term Liabilities $31.04M $31.04M $1.955M
Total Liabilities $46.15M $46.15M $12.77M
YoY Change 261.39% 261.39% 11.04%
SHAREHOLDERS EQUITY
Retained Earnings -$329.4M
YoY Change 30.8%
Common Stock $374.5M
YoY Change 4.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $46.27M $46.27M $112.4M
YoY Change
Total Liabilities & Shareholders Equity $92.42M $92.42M $125.2M
YoY Change -26.16% -26.16% 13.89%

Cashflow Statement

Concept 2022 Q4 2022 2021
OPERATING ACTIVITIES
Net Income -$19.63M -$77.53M -$66.37M
YoY Change -2.07% 16.81% 10.59%
Depreciation, Depletion And Amortization $728.0K $2.700M $2.200M
YoY Change 11.15% 22.73% 29.41%
Cash From Operating Activities -$15.29M -$65.07M -$53.67M
YoY Change 3.99% 21.24% 43.81%
INVESTING ACTIVITIES
Capital Expenditures $95.00K $2.714M $3.986M
YoY Change -106.9% -31.91% 107.06%
Acquisitions
YoY Change
Other Investing Activities -$325.0K -$238.0K -$1.380M
YoY Change 225.0% -82.75% -44.58%
Cash From Investing Activities -$420.0K -$2.952M -$5.366M
YoY Change -71.56% -44.99% 21.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.000K 34.06M 70.85M
YoY Change -99.98% -51.93% -9.31%
NET CHANGE
Cash From Operating Activities -15.29M -65.07M -53.67M
Cash From Investing Activities -420.0K -2.952M -5.366M
Cash From Financing Activities 1.000K 34.06M 70.85M
Net Change In Cash -15.71M -33.96M 11.81M
YoY Change 39.49% -387.47% -67.54%
FREE CASH FLOW
Cash From Operating Activities -$15.29M -$65.07M -$53.67M
Capital Expenditures $95.00K $2.714M $3.986M
Free Cash Flow -$15.38M -$67.78M -$57.65M
YoY Change 15.44% 17.57% 46.91%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
87885235
CY2022 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
250000
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
250000
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001680048
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 us-gaap Tax Credit Carryforward Expiration Date
TaxCreditCarryforwardExpirationDate
2033-12-31
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2200000
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.76
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
103432603
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-38191
CY2022 dei Entity Registrant Name
EntityRegistrantName
MUSTANG BIO, INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-3828760
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
377 Plantation Street
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Worcester
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01605
CY2022 dei City Area Code
CityAreaCode
781
CY2022 dei Local Phone Number
LocalPhoneNumber
652-4500
CY2022 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2022 dei Trading Symbol
TradingSymbol
MBIO
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
48800000
CY2022 dei Auditor Name
AuditorName
KPMG LLP
CY2022 dei Auditor Location
AuditorLocation
New York, NY
CY2022 dei Auditor Firm
AuditorFirmId
185
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75656000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
109618000
CY2022Q4 us-gaap Other Receivables
OtherReceivables
36000
CY2021Q4 us-gaap Other Receivables
OtherReceivables
50000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3160000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2038000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
78852000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
111706000
CY2022Q4 mbio Property Plant And Equipment Excluding Assets Under Construction
PropertyPlantAndEquipmentExcludingAssetsUnderConstruction
8440000
CY2021Q4 mbio Property Plant And Equipment Excluding Assets Under Construction
PropertyPlantAndEquipmentExcludingAssetsUnderConstruction
9025000
CY2022Q4 mbio Construction In Process Net
ConstructionInProcessNet
951000
CY2021Q4 mbio Construction In Process Net
ConstructionInProcessNet
2027000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1000000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1000000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
261000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
362000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2918000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1050000
CY2022Q4 us-gaap Assets
Assets
92422000
CY2021Q4 us-gaap Assets
Assets
125170000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
13731000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
9744000
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
766000
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
723000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
612000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
348000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15109000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10815000
CY2022Q4 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
270000
CY2021Q4 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
270000
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
27436000
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
0
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3334000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1685000
CY2022Q4 us-gaap Liabilities
Liabilities
46149000
CY2021Q4 us-gaap Liabilities
Liabilities
12770000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
250000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
250000
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
2807008
CY2021Q4 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
2536607
CY2022Q4 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
1109000
CY2021Q4 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
4329000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
374522000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
359906000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-329369000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-251844000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
46273000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
112400000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
92422000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
125170000
CY2022 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
62475000
CY2021 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
49864000
CY2022 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
1474000
CY2021 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
5842000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12210000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11017000
CY2022 us-gaap Operating Expenses
OperatingExpenses
76159000
CY2021 us-gaap Operating Expenses
OperatingExpenses
66723000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-76159000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-66723000
CY2022 mbio Grant Income
GrantIncome
1304000
CY2022 us-gaap Interest Income Other
InterestIncomeOther
689000
CY2021 us-gaap Interest Income Other
InterestIncomeOther
368000
CY2022 us-gaap Interest Expense Debt
InterestExpenseDebt
3359000
CY2021 us-gaap Interest Expense Debt
InterestExpenseDebt
15000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1366000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
353000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-77525000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-66370000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.76
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
103432603
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
87885235
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
98435000
CY2021 mbio Stock Issuance Common Stock Issuable During Period
StockIssuanceCommonStockIssuableDuringPeriod
4212000
CY2021 mbio Stock Issued During Period Value At Marketing Offering
StockIssuedDuringPeriodValueAtMarketingOffering
70622000
CY2021 mbio Stock Issued During Period Value Equity Fee On At Market Offering
StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering
1884000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
309000
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3308000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-66370000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
112400000
CY2022 mbio Stock Issuance Common Stock Issuable During Period
StockIssuanceCommonStockIssuableDuringPeriod
1109000
CY2022 mbio Stock Issued During Period Value At Marketing Offering
StockIssuedDuringPeriodValueAtMarketingOffering
6500000
CY2022 mbio Stock Issued During Period Value Equity Fee On At Market Offering
StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering
166000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
206000
CY2022 mbio Additions To Apic Equity Fees On Rwg Debt
AdditionsToApicEquityFeesOnRwgDebt
750000
CY2022 mbio Additions To Apic From Issuance Of Rwg Debt Warrants
AdditionsToApicFromIssuanceOfRwgDebtWarrants
384000
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2283000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-77525000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
46273000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-77525000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-66370000
CY2022 mbio Issuance Of Common Shares Equity Fee On At Market Offering
IssuanceOfCommonSharesEquityFeeOnAtMarketOffering
166000
CY2021 mbio Issuance Of Common Shares Equity Fee On At Market Offering
IssuanceOfCommonSharesEquityFeeOnAtMarketOffering
1884000
CY2022 mbio Adjustment To Recognize Effect Of Research And Development Expense Attributable To Asset Acquired Via Stock Issuance
AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance
1109000
CY2021 mbio Adjustment To Recognize Effect Of Research And Development Expense Attributable To Asset Acquired Via Stock Issuance
AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance
4212000
CY2022 mbio Research And Development License In Accounts Payable And Accrued Expense
ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense
365000
CY2021 mbio Research And Development License In Accounts Payable And Accrued Expense
ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense
1630000
CY2022 mbio Common Share Issuance Fees Related Party Debt
CommonShareIssuanceFeesRelatedPartyDebt
750000
CY2021 mbio Common Share Issuance Fees Related Party Debt
CommonShareIssuanceFeesRelatedPartyDebt
0
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
2283000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
3308000
CY2022 us-gaap Depreciation
Depreciation
2723000
CY2021 us-gaap Depreciation
Depreciation
2167000
CY2022 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
470000
CY2021 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
308000
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
139000
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-255000
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1021000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
401000
CY2022 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-14000
CY2021 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
35000
CY2022 mbio Increase Decrease In Accounts Payable And Accrued Expenses Excluding Amounts Due To Related Parties
IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties
5257000
CY2021 mbio Increase Decrease In Accounts Payable And Accrued Expenses Excluding Amounts Due To Related Parties
IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties
-408000
CY2022 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
43000
CY2021 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
233000
CY2022 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2021 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
270000
CY2022 mbio Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
263000
CY2021 mbio Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
296000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-65066000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-53667000
CY2022 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
365000
CY2021 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1380000
CY2022 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
127000
CY2021 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2714000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3986000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2952000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5366000
CY2022 mbio Proceeds From Issuance Of Common Shares At Market Offering
ProceedsFromIssuanceOfCommonSharesAtMarketOffering
6623000
CY2021 mbio Proceeds From Issuance Of Common Shares At Market Offering
ProceedsFromIssuanceOfCommonSharesAtMarketOffering
71919000
CY2022 mbio Offering Costs For Issuance Of Common Shares At Market Offering
OfferingCostsForIssuanceOfCommonSharesAtMarketOffering
123000
CY2021 mbio Offering Costs For Issuance Of Common Shares At Market Offering
OfferingCostsForIssuanceOfCommonSharesAtMarketOffering
1381000
CY2022 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
30000000
CY2021 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0
CY2022 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
2650000
CY2021 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
CY2022 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
206000
CY2021 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
309000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
34056000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
70847000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-33962000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
11814000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
110618000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
98804000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76656000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
110618000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
2710000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
0
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1270000
CY2022 us-gaap Stock Issued1
StockIssued1
4212000
CY2021 us-gaap Stock Issued1
StockIssued1
7577000
CY2022 mbio Research And Development Licenses Expenditure Incurred But Not Yet Paid
ResearchAndDevelopmentLicensesExpenditureIncurredButNotYetPaid
0
CY2021 mbio Research And Development Licenses Expenditure Incurred But Not Yet Paid
ResearchAndDevelopmentLicensesExpenditureIncurredButNotYetPaid
250000
CY2022 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
1050000
CY2021 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0
CY2022 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
384000
CY2021 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0
CY2022 mbio Lease Liabilities Arising From Obtaining Right Of Use Assets
LeaseLiabilitiesArisingFromObtainingRightOfUseAssets
2176000
CY2021 mbio Lease Liabilities Arising From Obtaining Right Of Use Assets
LeaseLiabilitiesArisingFromObtainingRightOfUseAssets
101000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-329400000
CY2022 mbio Number Of Subsidiaries
NumberOfSubsidiaries
0
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2200000
CY2017Q4 us-gaap Net Rentable Area
NetRentableArea
27043
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1000000.0
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1000000.0
CY2022 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P5Y
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Before Tax1
AccumulatedOtherComprehensiveIncomeLossBeforeTax1
0
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5443527
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7316869
CY2016Q3 mbio Preferred Stock Voting Rights Multiplier
PreferredStockVotingRightsMultiplier
1.1
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
17792000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16786000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8401000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5734000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9391000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11052000
CY2022 us-gaap Depreciation
Depreciation
2700000
CY2021 us-gaap Depreciation
Depreciation
2200000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6833000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3512000
CY2022Q4 mbio Research And Development Current
ResearchAndDevelopmentCurrent
2782000
CY2021Q4 mbio Research And Development Current
ResearchAndDevelopmentCurrent
3083000
CY2022Q4 mbio Accrued Compensation Current
AccruedCompensationCurrent
3468000
CY2021Q4 mbio Accrued Compensation Current
AccruedCompensationCurrent
2595000
CY2022Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
648000
CY2021Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
554000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
13731000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
9744000
CY2022Q2 us-gaap Net Rentable Area
NetRentableArea
26503
CY2017Q4 mbio Lessee Operating Lease Total Abatements Over Lease Term
LesseeOperatingLeaseTotalAbatementsOverLeaseTerm
600000
CY2017Q4 mbio Lessee Operating Lease Total Base Rent Net Of Abatements
LesseeOperatingLeaseTotalBaseRentNetOfAbatements
3600000
CY2017Q4 us-gaap Security Deposit
SecurityDeposit
800000
CY2017Q4 mbio Lessee Security Deposit Upon Full Occupancy
LesseeSecurityDepositUponFullOccupancy
1300000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3900000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2900000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2000000.0
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1100000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
565000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
315000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
488000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
599000
CY2022 us-gaap Lease Cost
LeaseCost
1053000
CY2021 us-gaap Lease Cost
LeaseCost
914000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
485000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
484000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y10M24D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y9M18D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.091
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.090
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
529000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
614000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1139000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1076000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
650000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
1381000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5389000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1443000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3946000
CY2022Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
400000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
85000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
25000000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
150000000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
150000000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
50000000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
200000000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
2283000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
3308000
CY2022 mbio Employee Stock Purchase Plan Predetermined Offering Period Lower Fair Market Value Percentage
EmployeeStockPurchasePlanPredeterminedOfferingPeriodLowerFairMarketValuePercentage
0.85
CY2022 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
586010
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
413990
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.16
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.16
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.01
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.01
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.05
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.05
CY2022 mbio Effective Income Tax Rate Reconciliation Change In Federal Enacted Tax Rate Percent
EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatePercent
0
CY2021 mbio Effective Income Tax Rate Reconciliation Change In Federal Enacted Tax Rate Percent
EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatePercent
0
CY2022 mbio Effective Income Tax Rate Reconciliation Change In State Enacted Tax Rate Percent
EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatePercent
0
CY2021 mbio Effective Income Tax Rate Reconciliation Change In State Enacted Tax Rate Percent
EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatePercent
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.01
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.42
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.41
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
75011000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
66879000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
2399000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
2702000
CY2022Q4 us-gaap Deferred Tax Assets Derivative Instruments
DeferredTaxAssetsDerivativeInstruments
59000
CY2021Q4 us-gaap Deferred Tax Assets Derivative Instruments
DeferredTaxAssetsDerivativeInstruments
59000
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
13375000
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
13977000
CY2022Q4 mbio Deferred Tax Asset Operating Lease Liabilities
DeferredTaxAssetOperatingLeaseLiabilities
1466000
CY2021Q4 mbio Deferred Tax Asset Operating Lease Liabilities
DeferredTaxAssetOperatingLeaseLiabilities
755000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
1434000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
1035000
CY2022Q4 mbio Deferred Tax Assets Start Up Costs
DeferredTaxAssetsStartUpCosts
6000
CY2021Q4 mbio Deferred Tax Assets Start Up Costs
DeferredTaxAssetsStartUpCosts
6000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
15649000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
9728000
CY2022Q4 mbio Deferred Tax Assets Capitalization Of Research And Development Expenses
DeferredTaxAssetsCapitalizationOfResearchAndDevelopmentExpenses
19787000
CY2021Q4 mbio Deferred Tax Assets Capitalization Of Research And Development Expenses
DeferredTaxAssetsCapitalizationOfResearchAndDevelopmentExpenses
0
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
129186000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
95141000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
128101000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
94751000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1085000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
390000
CY2022Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
1085000
CY2021Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
390000
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
128100000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
94800000
CY2021 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2022 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0

Files In Submission

Name View Source Status
tmb-20221231x10k_htm.xml Edgar Link completed
0001558370-23-004979-index-headers.html Edgar Link pending
0001558370-23-004979-index.html Edgar Link pending
0001558370-23-004979.txt Edgar Link pending
0001558370-23-004979-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20221231.xsd Edgar Link pending
tmb-20221231x10k.htm Edgar Link pending
tmb-20221231xex10d22.htm Edgar Link pending
tmb-20221231xex10d22001.jpg Edgar Link pending
tmb-20221231xex10d22002.jpg Edgar Link pending
tmb-20221231xex10d22003.jpg Edgar Link pending
tmb-20221231xex10d22004.jpg Edgar Link pending
tmb-20221231xex10d22005.jpg Edgar Link pending
tmb-20221231xex10d22006.jpg Edgar Link pending
tmb-20221231xex10d22007.jpg Edgar Link pending
tmb-20221231xex10d22008.jpg Edgar Link pending
tmb-20221231xex10d22009.jpg Edgar Link pending
tmb-20221231xex10d22010.jpg Edgar Link pending
tmb-20221231xex10d22011.jpg Edgar Link pending
tmb-20221231xex10d22012.jpg Edgar Link pending
tmb-20221231xex10d23.htm Edgar Link pending
tmb-20221231xex10d23001.jpg Edgar Link pending
tmb-20221231xex10d23002.jpg Edgar Link pending
tmb-20221231xex10d23003.jpg Edgar Link pending
tmb-20221231xex23d1.htm Edgar Link pending
tmb-20221231xex31d1.htm Edgar Link pending
tmb-20221231xex31d2.htm Edgar Link pending
tmb-20221231xex32d1.htm Edgar Link pending
tmb-20221231xex32d2.htm Edgar Link pending
tmb-20221231xex4d3.htm Edgar Link pending
tmb-20221231_def.xml Edgar Link unprocessable
tmb-20221231_cal.xml Edgar Link unprocessable
tmb-20221231_lab.xml Edgar Link unprocessable
tmb-20221231_pre.xml Edgar Link unprocessable